A Montreal study, to which research member Dr. Moishe Liberman contributed, shows that a drug increases the chances of survival for patients with non-small cell lung cancer (NSCLC), the most common form of lung cancer.
The drug, which restores the anti-tumor immune response, is combined with chemotherapy and administered before surgery.
The results of this study were published in the prestigious New England Journal of Medicine.
Manuela Santos’ team investigates the role of the gut microbiota
22 June 2021
The team of Dr. Manuela Santos, head of the Nutrition and Microbiome Laboratory at the CRCHUM and a member researcher […]
Dr. David Roberge: Appointment to the Canadian Association of Radiation Oncology
17 January 2022
The Institute would like to acknowledge the appointment of Dr. David Roberge as President-Elect of the Canadian Association of Radiation […]